Rosuvast 20 mg

Rosuvastatin 20 mg

Dosing & Uses
Adult

Dosage Forms & Strengths

tablet

  • 5 mg
  • 10 mg
  • 20 mg
  • 40 mg

Hypercholesterolemia

Hypertriglyceridemia, hyperlipidemia, mixed dyslipidemia, slowing progression of atherosclerosis, primary dysbetalipoproteinemia

10-20 mg PO qDay initially; may titrate; not to exceed 40 mg/day

Dosage range: 5-40 mg/day

Homozygous familial hypercholesterolemia: Initiate with 20 mg PO qDay; may titrate; not to exceed 40 mg/day

Primary Prevention

Primary prevention of cardiovascular disease in individuals with no clinically evident heart disease but who are at risk because of combined effect of risk factors listed below

Approval based on JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin)

Initial: 10-20 mg PO qDay

Dosage range 5-40 mg/day

Cardiovascular disease

  • Shown to reduce risk of stroke, MI, and arterial revascularization procedures (including CABG, bypass grafting of peripheral artery or carotid artery, and angioplasty or stent placement)

Risk factors

  • Age (>50 yr in men; >60 yr in women), AND
  • Elevated high-sensitivity C-reactive protein level (>2 mg/L), AND
  • Presence of at least 1 additional cardiovascular risk factor (eg, high blood pressure, low HDL-C, smoking, family history of premature heart disease)

Dosing Considerations

Patients of Asian descent: Initiate with 5 mg/day

Coadministration with other lipid-lowering therapy: Consider dose reduction if combined with niacin or fenofibrate, because of increased risk for skeletal muscle effects

Coadministration with cyclosporine: Not to exceed 5 mg/day

Coadministration with gemfibrozil: Avoid if possible; if used together, do not exceed 10 mg/day

Coadministration with ritonavir, lopinavir/ritonavir, or atazanavir/ritonavir: Not to exceed 10 mg/day

Overdose management

  • Adverse drug reactions from overdose may include peripheral neuropathy, diarrhea, increased K+, myopathy, rhabdomyolysis, acute renal failure, elevated LFTs, eye lens opacities
  • Treatment is supportive

Dosing Modifications

Renal impairment

  • Severe (CrCl <30 mL/min/1.73m²) and not on hemodialysis: Decrease starting dose to 5 mg PO qDay; not to exceed 10 mg PO qDay
  • CrCl>30mL/min/1.73m²: Dose adjustment not necessary
  • Active liver disease: Use is contraindicated
  • Chronic alcoholic liver disease is known to increase rosuvastatin exposure; caution advised
Pediatric
Dosage Forms & Strengths
tablet

  • 5 mg
  • 10 mg
  • 20 mg
  • 40 mg
Heterozygous Familial Hypercholesterolemia (HeFH)
Indicated to reduce total-C, LDL-C, and ApoB levels in children and adolescents aged 8-17 yr if after an adequate trial of diet therapy the following findings are present: LDL-C >190 mg/dL, or >160 mg/dL along with a positive family history of premature cardiovascular disease (CVD) or ≥2 CVD risk factors
<8 years: Safety and efficacy not established
8 to <10 years: 5-10 mg PO qDay
10-17 years: 5-20 mg PO qDay; may adjust dose at intervals of at least 4 wk; not to exceed 20 mg/day

Homozygous Familial Hypercholesterolemia (HoFH)
Indicated to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents aged 7 to 17 yr with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (eg, LDL apheresis)
<7 years: Safety and efficacy not established
7-17 years: 20 mg PO qDay

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Rosuvast 20 mg only for the indication prescribed.